Samuel Rosner, MD

Samuel Rosner, MD, and Laura Alder, MD, discuss ongoing research to watch in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss AE management and compliance strategies for patients with EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss how antibody-drug conjugates have affected the EGFR-mutated NSCLC treatment paradigm.

Samuel Rosner, MD, and Laura Alder, MD, discuss treatment approaches following frontline use of the MARIPOSA or FLAURA-2 regimens in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss how MET status and other factors can help inform sequencing decisions in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss combination vs monotherapy approaches in EGFR-mutated NSCLC.

Samuel Rosner, MD, and Laura Alder, MD, discuss factors that help inform frontline treatment selection in EGFR-mutated NSCLC.

Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.